Drugs / Tegodor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06538623 | Aug 2024 → Dec 2025 | metastatic neoplasm, pancreatic neoplasm | Ruijin Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tegodor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06538623 ↗ |
| Route | Oral | “taken orally” NCT06538623 ↗ |